Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:1909-1913
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000014683.52177.B5
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/16/1909    most recent
01.CIR.0000014683.52177.B5v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, C. M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Angioplasty
*Heart Attack
Related Collections
Right arrow Fibrinolysis
Right arrow Catheter-based coronary interventions: stents
Right arrow Acute myocardial infarction
Right arrow Angiography

(Circulation. 2002;105:1909.)
© 2002 American Heart Association, Inc.


Clinical Investigation and Reports

Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction

C. Michael Gibson, MS MD; Christopher P. Cannon, MD; Sabina A. Murphy, MPH; Susan J. Marble, RN MS; Hal V. Barron, MD; Eugene Braunwald, MD, for the TIMI Study Group

From the TIMI Study Group, Department of Medicine, Brigham and Women’s Hospital (C.M.G., S.A.M., S.J.M., C.P.C., E.B.), Boston, Mass, and the Cardiovascular Division, Department of Medicine, the University of California San Francisco (H.V.B.).

Correspondence to C. Michael Gibson, MS, MD, TIMI Study Group, 930 Commonwealth Ave, 3rd Floor, Boston, MA 02215. E-mail mgibson{at}perfuse.org


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Although 90-minute TIMI flow grades (TFGs), corrected TIMI frame counts (CTFCs), and TIMI myocardial perfusion grades (TMPGs) have been associated with 30-day outcomes, we hypothesized that these indices would be related to long-term outcomes after thrombolytic administration.

Methods and Results As a substudy of the TIMI 10B trial (tissue plasminogen activator versus tenecteplase), 49 centers carried out 2-year follow-up. TIMI grade 2/3 flow (Cox hazard ratio [HR] 0.41, P=0.001), reduced CTFCs (faster flow, P=0.02), and an open microvasculature (TMPG 2/3) (HR 0.51, P=0.038) were all associated with improved 2-year survival. Rescue percutaneous coronary intervention (PCI) of closed arteries (TFG 0/1) at 90 minutes was associated with reduced mortality (P=0.03), and mortality trended lower with adjunctive PCI of open (TFG 2/3) arteries (P=0.11). In a multivariate model correcting for previously identified correlates of mortality (age, sex, pulse, left anterior descending coronary artery infarction, and any PCI during initial hospitalization), patency (TFG 2/3) (HR 0.32, P<0.001), CTFC (P=0.01), and TMPG 2/3 remained associated with reduced mortality (HR 0.46, P=0.02).

Conclusions Both improved epicardial flow (TFG 2/3 and low CTFCs) and tissue-level perfusion (TMPG 2/3) at 90 minutes after thrombolytic administration are independently associated with improved 2-year survival, suggesting complementary mechanisms of improved long-term survival. Although rescue PCI reduced long-term mortality, improved microvascular perfusion (TMPG 2/3) before PCI was also related to improved mortality independently of epicardial blood flow and the performance of rescue or adjunctive PCI. Further prospective trials are warranted to re-examine the benefit of early PCI with thrombolysis.


Key Words: perfusion • blood flow • trials • myocardial infarction • thrombolysis


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Excellent epicardial blood flow, as assessed by use of either the TIMI flow grades (TFGs)16 or the corrected TIMI frame count (CTFC),7,8 and improved microvascular perfusion by use of the TIMI myocardial perfusion grade (TMPG)9 have been related to reduced in-hospital and 30-day mortality after administration of thrombolytics. The relationship of these 3 indices to long-term outcomes, however, has not been examined. Furthermore, the relationship of rescue/adjunctive PCI to long-term outcomes in the contemporary era of stenting and adjunctive glycoprotein (GP) IIb/IIIA inhibition is unknown. We hypothesized that both improved epicardial and improved myocardial perfusion would be related to lower long-term mortality and that the assessment of myocardial perfusion would add independent long-term prognostic information to the assessment of epicardial flow.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Follow-up data at 30 days were obtained in 98% of patients (865/882) in the TIMI 10B trial. A total of 49 centers enrolling 753 patients participated in this substudy and provided 2-year follow-up data in 583 patients (77.4%). TIMI 10B was a randomized comparison of tenecteplase (30, 40, and 50 mg) and 90-minute infusion of recombinant tissue plasminogen activator (Activase or alteplase).10 Angiography was performed at 90 minutes after administration of thrombolytic drugs.10 Nitroglycerin was administered every 15 minutes if the systolic blood pressure exceeded 110 mm Hg.10

Percutaneous coronary intervention (PCI) was performed at the discretion of the clinical investigator and was not mandated by protocol in TIMI 10B. Rescue PCI was defined as PCI performed within 150 minutes of initial thrombolytic treatment for patients with TFG 0 or 1 at 90 minutes (n=120/150, 80%). Adjunctive PCI was defined as PCI performed within 150 minutes of thrombolytic treatment for patients with TFG 2 or 3 at 90 minutes (n=105/668, 15.7%). Delayed PCI was defined as first PCI performed beyond 150 minutes after thrombolytic treatment (n=235/593, 39.6%). Patients who experienced a recurrent myocardial infarction (MI) before PCI were analyzed as medically treated patients, because recurrent MI presumably led to their intervention (n=9).

Recurrent MI was defined as in previous TIMI trials, as follows.10 Within 18 hours of thrombolytic therapy, recurrent ischemic discomfort >=30 minutes and new or recurrent ST-segment elevation >=0.1 mV were required. After 18 hours, a criterion of re-elevation of creatine kinase (CK)-MB to above the upper limits of normal (ULN) and increased by >=50% over the previous value was added. If quantitative CKMB was not available, it was required that the total CK be re-evaluated to more than twice the ULN and increased by >=25% of >=200 U/mL over the previous value; if re-elevated to less than twice normal, the CK was required to exceed the ULN by >=50% and the previous value by 2-fold or >=200 U/mL. After coronary angioplasty, the definition of recurrent infarction was new Q waves in >=2 leads and re-elevation of the CKMB (or total CK if CKMB was not available) to at least twice normal and >=50% above the previous value; after CABG, the latter criterion was set at a CKMB elevation >=5 times normal.

Visual Assessment of Flow
All angiographic end points were prospectively assessed at 90 minutes. The TFG, as previously defined,1 was assessed at the TIMI angiographic core laboratory by a single observer (C.M.G.), who was blinded to treatment assignment and clinical outcome. The CTFC was converted when necessary to be based on the most common filming speed in the United States of 30 frames per second.7,8 The TMPGs were assessed as previously defined.9 In brief, in TMPG 0, there is minimal or no myocardial blush; in TMPG 1, dye stains the myocardium and this stain persists on the next injection; in TMPG 2, dye enters the myocardium but washes out slowly so that dye is strongly persistent at the end of the injection; and in TMPG 3, there is normal entrance and exit of dye in the myocardium so that dye is mildly persistent at the end of the injection.

Statistical Analysis
Analyses were performed with Stata statistical software version 7.0.11 Variables were compared by the Fisher’s exact test or {chi}2 test for categorical data. Student’s t test or ANOVA was used for the analysis of normally distributed continuous variables. The nonparametric Wilcoxon rank sum test (for 2-way comparisons) or the Kruskal-Wallis test (for 3-way comparisons) was used to compare continuous variables when the data were not normally distributed or when data were imputed to an occluded vessel. The Cox hazard ratio (HR) model, Kaplan-Meier curves, and log-rank test were used in the survival analysis to test the equality of survival.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Baseline Characteristics by Mortality
Table 1 shows the association between selected baseline characteristics and mortality by 2 years in the TIMI 10B study. Expected high-risk clinical features were associated with mortality. Median duration of follow-up was 697 days (25th percentile 35, 75th percentile 820); however, for all analyses, data were censored at 730 days (2 years).


View this table:
[in this window]
[in a new window]
 
Table 1. Baseline Characteristics and Long-Term Mortality

Relation of TIMI Flow Indices to Mortality
TFG 2/3 (Cox HR 0.41, P=0.001), reduced CTFCs (faster flow) (HR 0.92 per 10-frame decrease, P=0.02), and an open microcirculation (TMPG 2/3) (HR 0.51, P=0.038) on the 90-minute angiogram were all associated with improved 2-year mortality in univariate analyses (Table 2, Figures 1 and 2), although TFG 3 was not (HR 0.68, P=0.12). An open microvasculature was also associated with reduced rates of death/MI (HR 0.64, P=0.044), whereas other parameters were not related to the end point of death or MI (Table 3). In a multivariate model correcting for previously identified correlates of death (age, sex, pulse, left anterior descending coronary artery infarction, and any PCI during initial hospitalization), the 90-minute patency (TFG 2/3) (HR 0.32, P<0.001), CTFC (HR 0.90 per 10-frame decrease, P=0.01), and TMPG 2/3 remained associated with reduced mortality (HR 0.46, P=0.02).


View this table:
[in this window]
[in a new window]
 
Table 2. Angiographic Characteristics and Long-Term Mortality



View larger version (16K):
[in this window]
[in a new window]
 
Figure 1. Kaplan-Meier survival curves for 2-year mortality by TFG at 90 minutes. Four-way log-rank P=0.003. Mortality trended lower in patients who had TFG 3 at 90-minute angiography (log-rank P=0.11).


View this table:
[in this window]
[in a new window]
 
Table 3. Angiographic Characteristics and Long-Term Mortality/Recurrent MI



View larger version (13K):
[in this window]
[in a new window]
 
Figure 2. Kaplan-Meier survival curves for 2-year mortality by TMPG at 90 minutes. Mortality was lower in patients who had an open microvasculature (TMPG 2/3) at 90-minute angiography (log-rank P=0.03).

Relation of PCI and Mortality
On univariate analysis, rescue PCI of closed arteries (TFG 0/1) was associated with improved mortality (log-rank P=0.031), whereas adjunctive PCI of open arteries (TFG 2/3) tended to be associated with lower long-term mortality (P=0.11), but delayed PCI did not (P=0.36) (Figures 3 and 4). The number of patients who received stents was not significantly different for patients who underwent delayed and adjunctive PCI (48% and 38%) but was higher for each of these than in patients who underwent rescue PCI (21%, P<0.005). After adjustment for use of stent (P=NS), rescue PCI remained associated with 2-year mortality in patients with closed arteries (HR 0.34, P=0.03), and a trend was seen for improved mortality in adjunctive (HR 0.31, P=0.070) and delayed (HR 0.49, P=0.15) PCI.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 3. Kaplan-Meier survival curves for 2-year mortality by use of rescue PCI in patients with TFG 0/1 at 90 minutes. Mortality was lower in patients who underwent rescue PCI after 90-minute angiography (log-rank P=0.03).



View larger version (13K):
[in this window]
[in a new window]
 
Figure 4. Kaplan-Meier survival curves for 2-year mortality by use of adjunctive and delayed PCI. Mortality trended lower in patients who underwent adjunctive and delayed PCI after 90-minute angiography (log-rank P=0.2).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The results presented here indicate that improved epicardial artery perfusion at 90 minutes after administration of thrombolytics is related to reduced long-term mortality by 2 years. Furthermore, independent of epicardial blood flow and the performance of PCI, improved microvascular perfusion as assessed by use of the TMPG is also related to reduced long-term mortality at 2 years. Thus, the TMPG adds additional long-term prognostic information to the conventional epicardial TFG and CTFC, again emphasizing that "not all TIMI grade 3 flow is created equally." To optimize outcomes, both epicardial and microvascular perfusion must be restored to normal. Because all 3 of these angiographic methods can be assessed by visual inspection of the angiogram, without the use of sophisticated equipment, each of these methods could be conveniently and broadly applied in clinical practice as a means of risk stratification of long-term survival on the basis of early angiography.

Long-Term Mortality Benefits of Rescue and Adjunctive PCI
As an adjunct to thrombolysis, PCI might improve flow, relieve residual stenoses, and reduce reocclusion. Despite these intuitive angiographic benefits, early randomized trials of adjunctive PCI in open vessels1214 and nonrandomized trials of rescue PCI in closed vessels1517 did not show a clinical benefit of angioplasty routinely performed immediately after thrombolysis over thrombolysis alone, probably because of a higher risk of intramural hemorrhage in the arterial wall and abrupt closure.1217 These trials are now outdated, because they preceded the widespread use of stents, aspirin, ticlopidine/clopidogrel, GP IIb/IIIA inhibitors, and the monitoring of activated clotting times. The recent Primary Angioplasty Alteplase Compatibility Trial (PACT) incorporated these current practice patterns and demonstrated that the 2 strategies (half dose of tissue plasminogen activator plus intervention) can be combined without increased risk of adverse outcomes over intervention alone.18 Schweiger et al19 also recently showed that in the TIMI 10B and 14 trials, which incorporated current practice patterns, patients with TFG 0 or 1 who underwent rescue PCI had lower 30-day mortality than those treated without PCI (6% versus 17%, P=0.01). The 30-day mortality of adjunctive PCI patients (3%) was similar to that of patients undergoing delayed PCI.19

Although previous studies of rescue/adjunctive PCI reported in-hospital or 30-day mortality,1219 the long-term follow-up reported here indicates that in the era of stenting, GP IIb/IIIA inhibition, and newer antiplatelet agents, patients undergoing rescue PCI for a closed vessel (TFG 0/1) have improved 2-year mortality compared with those not treated with a mechanical intervention. Only 3.1% of patients (18/583) were treated with a GP IIb/IIIA inhibitor, and none of these patients died. The favorable outcomes among patients treated with either adjunctive or rescue PCI may obscure differences in clinical outcomes among pharmacological regimens.

The TMPG was related to 2-year mortality independently of whether the patient underwent PCI. Recently, Stone et al20 also reported that myocardial blush provides in-hospital prognostic information in those patients undergoing either primary or rescue PCI. Even among patients with epicardial TFG 3 at the completion of the PCI, there was a significant gradient in in-hospital mortality, depending on the myocardial blush grade in the study by Stone et al.20 Our data now extend these initial observations to show the complementary benefit of complete epicardial flow and myocardial perfusion on long-term survival. Taken together, these angiographic data add to a growing body of literature linking impaired tissue-level perfusion on echocardiography or electrocardiography to adverse clinical outcomes in the acute MI setting.2126

Limitations
The reproducibility of the TMPG remains to be determined. Although 90-minute myocardial perfusion and epicardial coronary blood flow are both related to mortality, there are other causes of death that may be unrelated to 90-minute perfusion, such as intracranial hemorrhage, reinfarction, ventricular arrhythmias, and mechanical complications. Although rescue PCI was related to long-term outcomes, the impact of measured and unmeasured confounders may not have been adequately controlled for.

Conclusions
Three simple, readily available angiographic methods to assess angiographic outcomes are all related to long-term mortality at 2 years. After administration of thrombolytics in patients with acute MI, impaired perfusion of the myocardium on coronary arteriography as assessed by the TMPG is related to a higher risk of mortality that is independent of flow in the epicardial artery. The use of the TMPG permits risk stratification, even among patients with TFG 3 and among those undergoing PCI. Randomized trials are warranted to re-examine the benefit of early PCI with thrombolysis.


*    Acknowledgments
 
This study was supported in part by a grant from Genentech, Inc, South San Francisco, Calif, and Boehringer Ingelheim, Germany. Dr Barron is an employee of Genentech Inc.

Received December 28, 2001; revision received February 12, 2002; accepted February 12, 2002.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985; 31: 932–936.
  2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329: 1615–1622.
  3. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1989; 1: 1367–1369.
  4. Vogt A, Von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993; 21: 1391–1395.
  5. Karagounis L, Sorensen SG, Menlove RI, et al. Does thrombolysis in myocardial infarction TIMI perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol. 1992; 17: 1–10.
  6. Anderson JL, Karagounis LA, Becker LC, et al, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation. 1993; 87: 1829–1839.
  7. Gibson CM, Cannon CP, Daley WL, et al. The TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996; 93: 879–888.
  8. Gibson CM, Murphy SA, Rizzo MJ, et al. The relationship between the TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1999; 99: 1945–1950.
  9. Gibson CM, Cannon CP, Murphy SA, et al, for the TIMI study group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101: 125–130.
  10. Cannon CP, Gibson CM, McCabe CH, et al, for the TIMI 10B Investigators. TNK–tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation. 1998; 98: 2805–2814.
  11. Stata Corp. Stata Statistical Software: Release 7.0. College Station, Tex: Stata Corp; 2000.
  12. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987; 317: 581–588.
  13. Simoons ML, Col J, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988; 1: 197–203.
  14. The TIMI Research Group. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA. 1988; 260: 2849–2858.
  15. Ellis SG, Sliva ER, Heyndrickx G, et al, for the RESCUE investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation. 1994; 90: 2280–2284.
  16. Gibson CM, Cannon CP, Greene RM, et al, for the TIMI 4 study group. Rescue angioplasty in the TIMI 4 Trial. Am J Cardiol. 1997; 80: 21–26.
  17. McKendall GR, Forman S, Sopko G, et al, and the Thrombolysis in Myocardial Infarction investigators. Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol. 1995; 76: 1108–1111.
  18. Ross AM, Coyne KS, Reiner JS, et al, for the PACT investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol. 1999; 34: 1954–1962.
  19. Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction: the combined TIMI 10B-TIMI 14 experience. Am J Cardiol. 2001; 88: 831–836.
  20. Stone GW, Lansky AJ, Mehran R, et al. Beyond TIMI 3 Flow: the importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. J Am Coll Cardiol. 2000; 35: 403A.
  21. Van’t Hof AWJ, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998; 97: 2302–2306.
  22. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85: 1699–1705.
  23. Kenner MD, Zajac EJ, Kondos GT, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol. 1995; 76: 861–868.
  24. Sakuma T, Hayashi Y, Sumii K, et al. Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol. 1998; 32: 890–897.
  25. Marwick TH, Brunken R, Meland N, et al, for the Nycomed NC100100 Investigators. Accuracy and feasibility of contrast echocardiography for detection of perfusion defects in routine practice: comparison with wall motion and technetium-99m sestamibi single photon emission computed tomography. J Am Coll Cardiol. 1998; 32: 1260–1269.
  26. Maes A, Van de Werf F, Nuyts J, et al. Impaired myocardial tissue perfusion early after successful thrombolysis: impact on myocardial flow, metabolism, and function at late follow-up. Circulation. 1995; 92: 2072–2078.



This article has been cited by other articles:


Home page
Eur Heart JHome page
S. J. Brener, D. J. Moliterno, P. E. Aylward, A. W.J. van't Hof, W. Ruzyllo, W. W. O'Neill, C. W. Hamm, C. M. Westerhout, C. B. Granger, P. W. Armstrong, et al.
Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
Eur. Heart J., May 1, 2008; 29(9): 1127 - 1135.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
V. Stangl, V. Witzel, G. Baumann, and K. Stangl
Current diagnostic concepts to detect coronary artery disease in women
Eur. Heart J., March 2, 2008; 29(6): 707 - 717.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
E. Seyfeli, A. Abaci, M. Kula, R. Topsakal, N. K. Eryol, H. Arinc, I. Ozdogru, and A. Ergin
Myocardial Blush Grade: To Evaluate Myocardial Viability in Patients With Acute Myocardial Infarction
Angiology, November 1, 2007; 58(5): 556 - 560.
[Abstract] [PDF]


Home page
HeartHome page
J P Greenwood, J F Younger, J P Ridgway, M U Sivananthan, S G Ball, and S Plein
Safety and diagnostic accuracy of stress cardiac magnetic resonance imaging vs exercise tolerance testing early after acute ST elevation myocardial infarction
Heart, November 1, 2007; 93(11): 1363 - 1368.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. M. Marques, P. Knaapen, R. Boellaard, N. Westerhof, A. A. Lammertsma, C. A. Visser, and F. C. Visser
Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction
Eur. Heart J., October 1, 2007; 28(19): 2320 - 2325.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Fernandez-Aviles, J. J. Alonso, G. Pena, J. Blanco, J. Alonso-Briales, J. Lopez-Mesa, F. Fernandez-Vazquez, J. Moreu, R. A. Hernandez, A. Castro-Beiras, et al.
Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial
Eur. Heart J., April 2, 2007; 28(8): 949 - 960.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. G. Camici and F. Crea
Coronary Microvascular Dysfunction
N. Engl. J. Med., February 22, 2007; 356(8): 830 - 840.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. Mariani, R. Fetiveau, E. Rossetti, A. Poli, F. Poletti, P. Vandoni, M. D'Urbano, F. Cafiero, G. Mariani, C. Klersy, et al.
Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty
Eur. Heart J., November 1, 2006; 27(21): 2511 - 2515.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. B. Borden and D. P. Faxon
Facilitated Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1120 - 1128.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, D. A. Morrow, S. A. Murphy, T. M. Palabrica, L. K. Jennings, P. H. Stone, H. H. Lui, T. Bulle, N. Lakkis, R. Kovach, et al.
A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2364 - 2373.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
E Perez-David, M A Garcia-Fernandez, J Quiles, P Mahia, J L Lopez-Sendon, E Lopez de Sa, M J Ledesma, M Moreno, M Desco, and E Garcia
Usefulness of quantitative myocardial contrast echocardiography for prediction of ventricular function recovery after myocardial infarction treated with primary angioplasty.
Heart, May 1, 2006; 92(5): 693 - 694.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. G. Steg, L. Francois, B. Iung, D. Himbert, P. Aubry, P. Charlier, H. Benamer, L. J. Feldman, and J.-M. Juliard
Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction
Eur. Heart J., September 2, 2005; 26(18): 1831 - 1837.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Mizote, Y. Ueda, T. Ohtani, M. Shimizu, Y. Takeda, T. Oka, M. Tsujimoto, A. Hirayama, M. Hori, and K. Kodama
Distal Protection Improved Reperfusion and Reduced Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Who Had Angioscopically Defined Ruptured Plaque
Circulation, August 16, 2005; 112(7): 1001 - 1007.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, A. J. Kirtane, K. Boundy, H. Ly, D. Karmpaliotis, S. A. Murphy, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al.
Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients
J. Am. Coll. Cardiol., February 1, 2005; 45(3): 357 - 362.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Y Ohara, Y Hiasa, T Takahashi, K Yamaguchi, R Ogura, T Ogata, K Yuba, K Kusunoki, S Hosokawa, K Kishi, et al.
Relation between the TIMI frame count and the degree of microvascular injury after primary coronary angioplasty in patients with acute anterior myocardial infarction
Heart, January 1, 2005; 91(1): 64 - 67.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction
J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Iwakura, H. Ito, S. Kawano, A. Okamura, K. Tanaka, Y. Nishida, Y. Maekawa, and K. Fujii
Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices
Eur. Heart J., September 1, 2004; 25(17): 1526 - 1533.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. M. Gibson, L. K. Jennings, S. A. Murphy, D. P. Lorenz, R. P. Giugliano, R. A. Harrington, S. Cholera, R. Krishnan, R. M. Califf, E. Braunwald, et al.
Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment-Elevation Myocardial Infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) Substudy
Circulation, August 10, 2004; 110(6): 679 - 684.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. L. Grines and W. W. O'Neill
Rescue angioplasty: Does the concept need to be rescued?
J. Am. Coll. Cardiol., July 21, 2004; 44(2): 297 - 299.
[Full Text] [PDF]


Home page
CirculationHome page
C. M. Gibson and A. Schomig
Coronary and Myocardial Angiography: Angiographic Assessment of Both Epicardial and Myocardial Perfusion
Circulation, June 29, 2004; 109(25): 3096 - 3105.
[Full Text] [PDF]


Home page
CirculationHome page
W. F. Fearon, W. Aarnoudse, N. H.J. Pijls, B. De Bruyne, L. B. Balsam, D. T. Cooke, R. C. Robbins, P. J. Fitzgerald, A. C. Yeung, and P. G. Yock
Microvascular Resistance Is Not Influenced by Epicardial Coronary Artery Stenosis Severity: Experimental Validation
Circulation, May 18, 2004; 109(19): 2269 - 2272.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson
Confusion in reperfusion
J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1186 - 1187.
[Full Text] [PDF]


Home page
CirculationHome page
C. M. Gibson
Has My Patient Achieved Adequate Myocardial Reperfusion?
Circulation, August 5, 2003; 108(5): 504 - 507.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, J. Karha, S. A. Murphy, D. James, D. A. Morrow, C. P. Cannon, R. P. Giugliano, E. M. Antman, E. Braunwald, and TIMI Study Group
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials
J. Am. Coll. Cardiol., July 2, 2003; 42(1): 7 - 16.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. P.S. Henriques, F. Zijlstra, A. W.J. van 't Hof, M.-J. de Boer, J.-H. E. Dambrink, M. Gosselink, J. C.A. Hoorntje, and H. Suryapranata
Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade
Circulation, April 29, 2003; 107(16): 2115 - 2119.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. P. Lee, N. A. Herity, B. L. Hiatt, W. F. Fearon, M. Rezaee, A. J. Carter, M. Huston, D. Schreiber, P. M. DiBattiste, and A. C. Yeung
Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial
Circulation, March 25, 2003; 107(11): 1497 - 1501.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Dibra, J. Mehilli, J. Dirschinger, J.u. Pache, J. Neverve, M. Schwaiger, A. Schomig, and A. Kastrati
Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis
J. Am. Coll. Cardiol., March 19, 2003; 41(6): 925 - 929.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. K. Haager, P. Christott, N. Heussen, W. Lepper, P. Hanrath, and R. Hoffmann
Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion
J. Am. Coll. Cardiol., February 19, 2003; 41(4): 532 - 538.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Kern
Patterns of Left Ventricular Dilatation With an Opened Artery After Acute Myocardial Infarction: Missing Links to Long-Term Prognosis
Circulation, October 29, 2002; 106(18): 2294 - 2295.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/16/1909    most recent
01.CIR.0000014683.52177.B5v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend